MENU
+Compare
XPH
ETF ticker: NYSE ARCA
AS OF
Jun 4 closing price
Price
$41.14
Change
+$0.01 (+0.02%)
Net Assets
142.02M

XPH stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U... Show more

Category: #Health
XPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for XPH with price predictions
Jun 04, 2025

XPH in upward trend: 10-day moving average broke above 50-day moving average on May 30, 2025

The 10-day moving average for XPH crossed bullishly above the 50-day moving average on May 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 28, 2025. You may want to consider a long position or call options on XPH as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

XPH moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XPH advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Pharmaceuticals ETF ETF is 64.17B. The market cap for tickers in the group ranges from 195.7M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is OMER at 195.7M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was 2%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was -10%. ELVN experienced the highest price growth at 39%, while CORT experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was 15%. For the same stocks of the ETF, the average monthly volume growth was -20% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 71
Price Growth Rating: 58
SMR Rating: 68
Profit Risk Rating: 76
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
XPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com